Scholarlink

Background <p>FGFR2b is a new emerging therapeutic target in gastric cancer (GC). This study aimed to examine the clinicopathological characteristics of FGFR2b and its relationship with key biomarkers in locally advanced (LA) and metastatic or unresectable (MU) GC.</p> Methods <p>FGFR2b immunohistochemistry (IHC) (FPR2-D) positivity was defined as 2 or 3+ in any tumor cells. Additional tests included IHC for CLDN18.2 (43-14 A), HER2, PD-L1 (22C3), microsatellite instability testing, and Epstein–Barr virus ISH.</p> Results <p>Of the 1331 patients, 39 (2.9%) and 25 (1.9%) had FGFR2b-positive GC in any % and in ≥10% of tumor cells, respectively. A higher FGFR2b-positivity rate was significantly associated with MU GC and a shorter interval between tumor acquisition and FGFR2b testing. HER2, PD-L1, and CLDN18.2 positivity rates did not differ by FGFR2b status. Intratumoral heterogeneity was observed in 88.0% of FGFR2b-positive resected cases. FGFR2b-positive GC had a trend toward shorter overall survival regardless of clinical factors.</p> Conclusion <p>FGFR2b positivity was higher in MU GC and in GC samples with shorter storage periods. However, no significant association was observed between FGFR2b expression and other key biomarkers or survival outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comprehensive analysis of FGFR2b and its correlation with essential biomarkers, intratumoral heterogeneity, and survival in advanced gastric cancer

  • 期刊论文

  • 发表日期：

    2026年3月27日

查看全文
  • Yoonjin Kwak,
  • Tae-Yong Kim,
  • Hye Seung Lee,
  • Soo Kyung Nam,
  • Hyeon Jeong Oh,
  • Do-Youn Oh,
  • Seock-Ah Im

摘要

Background

FGFR2b is a new emerging therapeutic target in gastric cancer (GC). This study aimed to examine the clinicopathological characteristics of FGFR2b and its relationship with key biomarkers in locally advanced (LA) and metastatic or unresectable (MU) GC.

Methods

FGFR2b immunohistochemistry (IHC) (FPR2-D) positivity was defined as 2 or 3+ in any tumor cells. Additional tests included IHC for CLDN18.2 (43-14 A), HER2, PD-L1 (22C3), microsatellite instability testing, and Epstein–Barr virus ISH.

Results

Of the 1331 patients, 39 (2.9%) and 25 (1.9%) had FGFR2b-positive GC in any % and in ≥10% of tumor cells, respectively. A higher FGFR2b-positivity rate was significantly associated with MU GC and a shorter interval between tumor acquisition and FGFR2b testing. HER2, PD-L1, and CLDN18.2 positivity rates did not differ by FGFR2b status. Intratumoral heterogeneity was observed in 88.0% of FGFR2b-positive resected cases. FGFR2b-positive GC had a trend toward shorter overall survival regardless of clinical factors.

Conclusion

FGFR2b positivity was higher in MU GC and in GC samples with shorter storage periods. However, no significant association was observed between FGFR2b expression and other key biomarkers or survival outcomes.